ScreenerHero

DRMA Dermata Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · dermatarx.com
1.120USD-0.89%Mkt Cap: 5.55M $P/E: —

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, incl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.55M USD
Enterprise Value132.26K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.56M USD
Revenue/Share—
Last Price1.120 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.29
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.30
EPS (TTM)-4.35
EPS (Forward)-3.87
52W Range
0.95093% of range5.870
52W High5.870 USD
52W Low0.9509 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-121.45%
ROA-96.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.76M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-92.09%
Net Debt-4.41M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio2.81
Quick Ratio2.41
Book Value/Sh0.87 USD
Cash/Share1.10 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateAug 1, 2025
Analyst Consensus
Rating—
Target (Mean)4.000 USD
Upside (mean)+257.1%
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.4.96M
Float2.90M
Insiders27.35%
Institutions7.77%
Short Interest
Short Ratio1.3d
Short % Float2.94%
Short % Out.2.42%
Shares Short120.02K
Short (prev mo.)366.82K
Technical
SMA 501.249 (-10.3%)
SMA 2001.436 (-22.0%)
Beta0.66
S&P 52W Chg16.45%
Avg Vol (30d)54.23K
Avg Vol (10d)25.12K
Technical Indicators
RSI (14)42.8
MACD-0.0412
MACD Signal-0.0427
MACD Hist.+0.0015
BB Upper1.226 USD
BB Middle1.147 USD
BB Lower1.068 USD
BB Width13.80%
ATR (14)0.0774 USD
Vol Ratio (20d)0.30x